Preprint
Investigating the Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy: Results of the SEL-I-METRY Phase II Trial
Authors
Wadsley J; Ainsworth G; Coulson AB; Garcez K; Moss L; Newbold K; Farnell K; Swain J; Howard H; Beasly M
Publication date
January 1, 2022
DOI
10.2139/ssrn.4143123
Preprint server
SSRN Electronic Journal